Combining thiotepa and pomalidomide for treating relapsed primary central nervous system lymphoma

A Single-arm, Prospective, Multicenter Clinical Trial of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma.

This study is testing a new combination of two drugs, thiotepa and pomalidomide, to see if they can help people with relapsed primary central nervous system lymphoma feel better after their previous treatments didn't work.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: The First Affiliated Hospital with Nanjing Medical University (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Nanjing, Jiangsu)
• Trial ID: NCT05931328 on ClinicalTrials.gov

What this trial studies

This study evaluates the efficacy and safety of a combination treatment using thiotepa and pomalidomide for patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). Participants must have a confirmed diagnosis of PCNSL and have previously undergone chemotherapy with disease progression. The study aims to determine how well this combination works in managing the disease and improving patient outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 75 with pathologically confirmed relapsed or refractory PCNSL who have previously received chemotherapy.

Not a fit: Patients who have not been previously treated with chemotherapy or those with severe organ dysfunction may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat relapsed or refractory PCNSL.

How similar studies have performed: While there is limited information on similar combinations, the approach of using thiotepa and pomalidomide together is relatively novel in this context.

Eligibility criteria

Inclusion Criteria:

Pathologically confirmed PCNSL, diagnosed according to the 2016 WHO diagnostic criteria. Previously treated with at least one course of chemotherapy, with disease progression or recurrence.

Aged 18 to 75 years old; ECOG PS score of 0 to 4 points; Expected survival time of more than 3 months; A whole-body PET/CT and head MR (plain scan + enhancement) performed within 28 days before study enrollment should show at least one measurable lesion in two perpendicular directions (based on the 2014 Lugano criteria), or abnormal findings in cerebrospinal fluid examination (including cerebrospinal fluid cells, NGS), or ocular examination confirming lesions in the retina or vitreous body;

Adequate organ function, defined as follows:

Liver function: serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Renal function: serum creatinine (Cr) ≤ 1 × ULN or creatinine clearance rate (CCR) ≥ 90 mL/min; Cardiac function: cardiac function grade of III or less (NYHA standard); echocardiography shows an ejection fraction of ≥50%; Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 10s, and prothrombin time (PT) ≤ 3s; Thyroid function: baseline thyroid-stimulating hormone (TSH) level is normal or baseline TSH is abnormal, but T3/T4 is normal and there are no symptoms; Women of childbearing age must take contraceptive measures or undergo a pregnancy test with a negative result before enrollment, and take contraceptive measures during the trial and within 90 days after the last dose of the drug; for men, contraceptive measures must be taken during the trial and within 90 days after the last dose of the drug, or they must have undergone surgical sterilization; The subject voluntarily agrees to participate in the study, signs an informed consent form, has good compliance, and cooperates with follow-up.

Exclusion Criteria:

Pregnant or lactating women; Patients with involvement of sites other than the central nervous system; Patients with bone marrow failure, specifically defined as absolute neutrophil count (ANC) \<1.5 x 109/L, platelets \<75 x 109/L, and hemoglobin \<70 g/L;

Patients diagnosed with malignant tumors other than lymphoma or currently undergoing treatment, with the following exceptions:

* Patients who have received curative treatment and have not had any known active malignant tumors for ≥5 years prior to enrollment; ② Patients with adequately treated basal cell carcinoma of the skin without evidence of disease (excluding melanoma); ③ Patients with adequately treated cervical intraepithelial neoplasia without evidence of disease.

Known allergy to any component of the investigational drug; Patients who have undergone allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Patients who may receive other systemic anti-tumor therapy during the study period; Patients with human immunodeficiency virus (HIV) antibodies, active hepatitis, or other uncontrolled infectious diseases; Patients with a history of clear neurological or psychiatric disorders; Patients who may interfere with the participation of the subject in the study or the evaluation of study results due to drug abuse, medical, psychological or social conditions; Patients deemed unsuitable for enrollment by the investigator.

Where this trial is running

Nanjing, Jiangsu

• Jiangsu Province People's Hospital. — Nanjing, Jiangsu, China (Recruiting)

Study contacts

• Study coordinator: Wei Xu, PhD

Conditions Relapsed or Refractory Primary Central Nervous System Lymphoma